Resources
Explore our growing library of research, presentations, and technical materials. These resources showcase the collaborative work of our partners and the progress made across each stage of the translational pipeline.
Revolutionizing tuberculosis regimen development
Same class, different activity: Delamanid and pretomanid have comparable bactericidal activity but pretomanid potently inhibits Mycobacterium tuberculosis ribosomal rRNA synthesis
Phase 2C clinical trial of novel short-course regimens for the treatment of pulmonary tuberculosis: TBTC study 38/CRUSH-TB design
Deconvoluting drug interactions using M. tuberculosis physiologic processes: transcriptional disaggregation of the BPaL regimen in vivo
Translational Modeling of BTZ-043 to Predict Phase 2A Efficacy and Evaluate Drug-Drug Interactions With Bedaquiline, Pretomanid, and Linezolid in Murine Models
Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy- or hard-to-treat tuberculosis disease
ACTG A5409 (RAD-TB): Study Protocol for a Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during prolonged treatment of mice
Savic receives NIH funding to establish tuberculosis Consortium
Rada Savic, PhD, co-vice dean of Graduate Pharmacy Education Programs at the UCSF School of Pharmacy..
NIH funds consortium to speed TB treatment development
A new consortium co-led by Weill Cornell Medicine has been awarded a five-year, $31 million grant from the..
.avif)
NIH Awards UM1 Funding to Establish PReDicTR Consortium
Rada Savic, PhD and colleagues Eric Nuermberger, MD (JHU), Kelly Dooley, MD, PhD, MPH (Vanderbilt), and..
.avif)
NIH Funds Consortium to Accelerate Development of New TB Treatments
A new consortium co-led by Weill Cornell Medicine, has been awarded a five-year, $31 million grant from the..
.avif)
.avif){kind=small}
PReDiCTR Logo & Brand Assets
The logo depicts an interconnected network of nodes, symbolizing the systematic integration of heterogeneous data streams spanning preclinical models, biological assays, and translational evidence. This unified architecture reflects a data-driven framework designed to enable predictive insight into future clinical trial outcomes.
Download official PReDiCTR logos in multiple formats and sizes for use in presentations, publications, and partner materials.
